Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pur...
BRT Apartments Corp. Announces Quarterly Dividend GREAT NECK, N.Y., June 04, 2025 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE: BRT) announced today that its Board of Directors declared a quarterly dividend of $0.25 per share. The dividend is payable on July 9, 2025, to stockholders of record at the close of business on June 25, 2025. BRT is a real estate investment trust that owns, operates and, to a lesser extent, holds interests in joint ventures that own multi-family properties. As of March 31, 2025, BRT owns or has interests in 29 multi-family properties with 7,947 units in 11 sta...
A director at BRT Apartments Corp bought 19,360 shares at 15.559USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eligible patients Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash ...
BRT Apartments Corp. Files First Quarter 2025 Financial Statements GREAT NECK, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE:BRT), a real estate investment trust, announced today that it has filed its quarterly report on Form 10-Q for the quarter ended March 31, 2025 with the Securities and Exchange Commission. The financial statements and can be accessed on the Company’s investor relations under the caption “Financials – Quarterly Results.” BRT is a real estate investment trust that owns, operates and, to a lesser extent, holds interests in joint ventures that own ...
Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Summary: Net revenue of $86.7 million for the first quarter of 2025, a decrease of $23.3 million compared to n...
Organogenesis Supports CMS’ Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness Organogenesis recommends CMS also implement an integrated coverage and payment policy CANTON, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets supports the U.S. Centers for Medicare & Me...
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025 CANTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, May 8th. Management will host a conference call at 5:00 p.m. Eastern Time ...
Nkarta to Participate in an April Investor Conference SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 24th Annual Needham Virtual Healthcare ConferenceApril 8, 202511:00 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, , and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is...
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimmune indications expected in second half of 2025Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestonesCash b...
BRT Apartments Corp. Files Fourth Quarter and Full Year 2024 Financial Statements GREAT NECK, N.Y., March 12, 2025 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE: BRT) announced today that it has filed its annual report on Form 10-K for the year ended December 31, 2024, with the Securities and Exchange Commission. The financial statements and can be accessed on the Company’s investor relations under the caption “Financials – Quarterly Results.” BRT is a real estate investment trust that owns, operates, and, to a lesser extent, makes preferred equity investments in joint ventures ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.